20226 ⎘
Medicinal preparations containing organic active ingredients; Amines Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
Methods for treating or preventing neuroinflammation or autoimmune diseases
#302Pharmaceutical combination comprising a CIP2A silencing agent for use in the treatment of a hyperproliferative disorder, preferably one with impaired P53 function
#303MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY
#304Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation
#305Substituted bicyclic compounds
#306Methods of treating posttraumatic stress disorder with acamprosate salts
#307Medicinal drug with activity against gram positive bacteria, mycobacteria and fungi
#308MAO inhibitors and their conjugates as therapeutics for the treatment of brain cancer
#309Adjuvant chemotherapy for anaplastic gliomas
#310SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS
#311Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use
#312Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
#313Targeted delivery of antimicrobial agents
#314Chemotherapeutic drug combination
#315Treatment of viral infections by modulation of host cell metabolic pathways
#316Use of Sigma-1 receptor agonist compounds
#317Methods and compositions for the treatment of cancer
#318LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE
#319MAO inhibitors and their conjugates as therapeutics for the treatment of brain cancer
#320Methods and compositions for identification of prostate cancer markers
#321Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
#322Pharmacological treatment of obsessive-compulsive disorder
#323NRF2 INHIBITORS AND COMPOSITIONS FOR TREATING MYCOBACTERIAL INFECTIONS
#324Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
#325Polyfunctional radical scavenger hydrogel formulation
#326Methods of treating tinnitus
#327Continuous administration of dopa decarboxylase inhibitors and compositions for same
#328Methods and compositions for modulating cancer stem cells
#329Antiviral compounds and methods of use thereof
#330Suicidal LSD1 inhibitors targeting SOX2-expressing cancer cells
#331Animal training using cognitive enhancement
#332N-(4-(bis(4-(dimethylamino)phenyl)methylene)-8-(dimethylamino)
#333BRIDGE-HELIX CAP: TARGET AND METHOD FOR INHIBITION OF BACTERIAL RNA POLYMERASE
#334CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS
#335Medicinal drug with activity against gram positive bacteria, mycobacteria and fungi
#336TGF-beta enhancing compositions for cartilage repair and methods related thereto
#337Treatment of neurological disorders
#338Methods and compositions for treatment of demyelinating diseases
#339Drug for killing acid-fast (red) bacillus
#340Shikonin, alkannin; and racemic parent nucleus cabonyl oxime derivatives and applications thereof
#341Preventive or therapeutic agent for pain associated with herpes zoster in acute phase
#342Method for treating/preventing disease using cognitive ability of cerebrum and pharmaceutical
#343Treatment of muscular dystrophies and associated conditions by administration of monoamine oxidase inhibitors
#344METHOD FOR TREATING OBESITY WITH ANTI-OBESITY FORMULATIONS AND OMEGA 3 FATTY ACIDS FOR THE REDUCTION OF BODY WEIGHT IN CARDIOVASCULAR DISEASE PATIENTS (CVD) AND DIABETICS
#345Doxorubicin adjuvants to reduce toxicity and methods for using the same
#346Hematopoietic growth factor mimetic small molecule compounds and their uses
#347Therapy and kit for the prevention and treatment of cystic fibrosis
#348Lysine demethylase inhibitors for myeloproliferative disorders
#349Treatments for depression and other diseases with a low dose agent
#350Inhibitors targeting drug-resistant influenza A
#351Anti-proliferative compounds and uses thereof
#352Treatment of urinary incontinence using nitrone spin traps
#353Treatment of urinary incontinence using nitrone spin traps
#354p62-ZZ chemical inhibitor
#355INHIBITORS OF HIPPO-YAP SIGNALING PATHWAY
#356Selective inhibitors of undifferentiated cells
#357Methods for selecting medications
#358Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
#359Acamprosate formulations, methods of using the same, and combinations comprising the same
#360Multi-step connective tissue stabilization method and stabilized tissue formed thereby
#361Preventing or treating viral infection using an inhibitor of the LSD1 protein, a MAO inhibitor or an inhibitor of LSD1 and a MAO inhibitor
#362LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE
#363Treatment of circadian rhythm disorders
#364BISPHENOL ETHER COMPOUNDS WITH NOVEL BRIDGING GROUPS AND METHODS FOR THEIR USE
#365Oximes for treatment of peripheral and central nervous system exposure to acetyl cholinesterase inhibitors
#366SMALL MOLECULE SCREEN FOR INHIBITORS OF NFAT: AP-1: DNA INTERACTIONS
#367Pharmaceutical composition for preventing or treating diabetes or fatty liver containing a CYP4A inhibitor as an active ingredient
#368SPINTRAPS AND SPIN LABELS AND THEIR HYDROXYLAMINES FOR PERI- AND POST-MENOPAUSAL SYNDROME
#369Tumor necrosis factor inhibitors
#370MODULATORS OF MITOCHONDRIAL PROTEIN IMPORT
#371Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
#372Adjuvant chemotherapy for anaplastic gliomas
#373Methods for inhibiting redox-sensitive GTPases
#374Pharmaceutical combination comprising a CIP2A silencing agent for use in the treatment of a hyperproliferative disorder, preferably one with impaired p53 function
#375Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
#376Methods for treating brain injury
#377Spin Traps and Spin Labels for the Treatment of Rectal Hemorrhoids
#378CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS
#379Methods of reducing levels of tau
#380Preventive or therapeutic agent for pain associated with herpes zoster in acute phase
#381Substituted cathechols as inhibitors of IL-4 and IL-5 for the treatment of bronchial asthma
#382CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS
#383Compositions for preventing and/or treating lysosomal storage disorders
#384PDE10 inhibitors and related compositions and methods
#385Bridge-helix cap: target and method for inhibition of bacterial RNA polymerase
#386Acamprosate formulations, methods of using the same, and combinations comprising the same
#387Acamprosate formulations, methods of using the same, and combinations comprising the same
#388NOVEL COMPOSITIONS COMPRISING A PHOSPHODIESTERASE-5 INHIBITOR AND THEIR USE IN METHODS OF TREATMENT
#389Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
#390MODULATION OF NITRIC OXIDE SIGNALING TO NORMALIZE TUMOR VASCULATURE
#391Methods and use of compounds that bind to Her2/neu receptor complex
#392Methods And Compositions For Treatment Of Lipogenic Virus Related Conditions
#393Methods for treatment of diseases and disorders related to transducin β-like protein 1 (TBL1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
#394Lysine demethylase inhibitors for diseases and disorders associated with
#395Topical antimicrobial compositions and methods of using same
#396Tumor necrosis factor inhibitors
#397Treatment of viral infections by modulation of host cell metabolic pathways
#398Small molecule inhibitors of protein kinases
#399Bis[thiohydrazide amide] compounds for treating leukemia
#400Oximes for treatment of peripheral and central nervous system exposure to acetyl cholinesterase inhibitors
#401ANTIVIRAL COMPOUNDS AND METHODS
#402Method of Administering Pirfenidone Therapy
#403Antimicrobial compositions and methods of use thereof
#404Treatment of muscular dystrophies and associated conditions by administration of monoamine oxidase inhibitors
#405Doxorubicin adjuvants to reduce toxicity and methods for using the same
#406Treatment of respiratory disorders using TRPA1 antagonists
#407Hematopoietic growth factor mimetic small molecule compounds and their uses
#408METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALCOHOLISM AND ALCOHOL DEPENDENCE
#409Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
#410Compositions For The Treatment of Central Nervous System Disorders Including Depression Employing Novel Drug Combination Therapy To Reduce Suicidality In Patients
#411Treatment of urinary incontinence using nitrone spin traps
#412Treatment of Psoriasis Using Oral Dosage Forms of Nitrone Spin Traps
#413Topical nitrone spin trap compositions for psoriasis
#414Methods for treating acute acoustic trauma
#415METHOD OF TREATING SLEEP DISORDERS USING THE COMBINATION OF EPLIVANSERIN AND ZOLPIDEM
#416Compositions for inhibiting redox-sensitive GTPases
#417LYSINE-SPECIFIC DEMETHYLASE 1(LSD1) IS A BIOMARKER FOR BREAST CANCER
#418Agent for preventing and treating pityriasis versicolor
#419METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE (PKD) OR OTHER CYST FORMING DISEASES
#420Nitrone, nitroso, and nitroxide spintraps and spin labels and their hydroxylamines
#421METHOD OF TREATING SLEEP DISORDERS USING EPLIVANSERIN
#422Compositions For The Treatment of Central Nervous System Disorders Including Depression Employing Novel Drug Combination Therapy To Reduce Suicidality In Patients
#423COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY
#424CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS
#425Transdermal preparation
#426Tuberculosis treatment using pleuromutilin derivatives
#427MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY
#428Methods of Administering Pirfenidone Therapy
#429Methods of administering pirfenidone therapy
#430Methods for the reactivation of latent HIV using cytosine methylation inhibitors and NF-KB activators
#431EFFECTS OF NITRIC OXIDE (NO) AND iNOS ON EXPRESSION AND SIGNAL TRANSDUCTION IN CANCER AND ITS USE IN DRUG DISCOVERY AND CANCER THERAPY DESIGN
#432ACTIVATED WNT-BETA-CATENIN SIGNALING IN MELANOMA
#433SURGICAL COMPOSITIONS CONTAINING SIGMA-RECEPTOR AGONISTS
#434Small molecules for inhibition of protein kinases
#435Treating renal cancer using 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2-methyl-benzaldehyde
#436Continuous administration of dopa decarboxylase inhibitors and compositions for same
#437Difluorophenyldiacylhydrazide derivatives
#438DNA CYTOSINE DEAMINASE INHIBITORS
#439Treating psychological conditions using muscarinic receptor Mantagonists
#440Use of targeted nitroxide agents in mitigating or treating radiation injury
#441Methods of administering pirfenidone therapy
#442Preventing or treating viral infection using an inhibitor of the LSD1 protein, a MAO inhibitor or an inhibitor of LSD1 and a MAO inhibitor
#443Method to treat infections using anti-infective agents
#444METHOD FOR TREATING/PREVENTING DISEASE USING COGNITIVE ABILITY OF CEREBRUM AND PHARMACEUTICAL
#445Compositions for preventing and/or treating lysosomal storage disorders
#446Nitric oxide donors for inducing neurogenesis
#447CCR5 ANTAGONISTS AS PROPHYLACTICS FOR PREVENTING HIV INFECTION AND METHODS OF INHIBITING TRANSMISSION OF SAME
#448Methods and Compositions Using Cholinesterase Inhibitors
#449Compositions comprising a phoshodiesterase-5 inhibitor and their use in methods of treatment
#450COMPOSITIONS AND METHODS FOR REDUCING FOOD CRAVINGS
#451Treating Negative Symptoms of Schizophrenia Associated with Defective Neuregulin 1
#452URETHRAL SUPPOSITORIES FOR OVERACTIVE BLADDER
#453β-phenylethylidenehydrazine derivatives
#454COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING
#455Continuous administration of dopa decarboxylase inhibitors and compositions for same
#456Continuous administration of dopa decarboxylase inhibitors and compositions for same
#457Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
#458TREATMENT OF NEUROLOGICAL DISORDERS
#459COMBINATION OF A LONG-ACTING HYPNOTIC AGENT AND A SHORT-ACTING HYPNOTIC AGENT AND THERAPEUTIC USE THEREOF
#460ESTROGEN RECEPTOR-RELATED RECEPTOR GAMMA (ERR GAMMA) IN BONE AND CARTILAGE FORMATION AND METHODS AND COMPOSITIONS RELATING TO SAME
#461BLOCKERS OF SEROTONIN AND ITS RECEPTORS FOR THE TREATMENT OF HEPATITIS
#462Inhibition of Bacterial Protein Production by Polyvalent Oligonucleotide Modified Nanoparticle Conjugates
#463POI Prevention
#464Film preparation with rapidly dissolving property and flexibility
#465Method of treating amblyopia
#466MODULATION OF NITRIC OXIDE SIGNALING TO NORMALIZE TUMOR VASCULATURE
#467Adjuvant chemotherapy for anaplastic gliomas
#468Treatment of cancer with bio and chemotherapy
#469PDE10 inhibitors and related compositions and methods
#470Targeted delivery of antimicrobial agents
#471Methods for treating acute acoustic trauma
#472Doxorubicin adjuvants to reduce toxicity and methods for using the same
#473Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases
#474Use of 3,5-seco-4-nor-cholestane derivatives for obtaining a cytoprotective drug
#475METHOD OF MODULATING CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME
#476XANTHINE DERIVATIVES FOR THE TREATMENT OF VASCULAR DEPRESSION
#477HYDRAZONE AGENTS TO TREAT CUTANEOUS LESIONS
#478PHARMACEUTICAL COMPOSITION COMPRISING, IN COMBINATION, SAREDUTANT AND ESCITALOPRAM
#479PHARMACEUTICAL COMPOSITION COMPRISING, IN COMBINATION, SAREDUTANT AND PAROXETINE
#480Treatment of viral infections by modulation of host cell metabolic pathways
#481PHARMACEUTICAL COMPOSITION COMPRISING, IN COMBINATION, SAREDUTANT AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR OR A SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITOR
#482Tumor necrosis factor inhibitors
#483CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS
#484TRPA1 antagonists
#485Stimulators of 5-HT4 receptors and uses thereof
#486Pharmaceutical composition on basis of reverse transcriptase inhibitor and meldonium
#487Treating renal cancer using a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde
#488COMPOSITIONS AND METHODS RELATED TO HEART FAILURE
#489METHODS FOR REDUCING HOSPITALIZATIONS RELATED TO HEART FAILURE
#490Use of compounds for the prevention of drug-induced cell toxicity
#491CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS
#492Methods for treating or preventing neuroinflammation or autoimmune diseases
#493METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS
#494Methods and Compositions Using Cholinesterase Inhibitors
#495New utilities of tricyclic compounds
#496Treatment of Disorders and Diseases of the Colon
#497Methods Using Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate
#498Propofol analogs, process for their preparation, and methods of use
#499PRIMARY N-HYDROXYLAMINES
#500Preventive or Therapeutic Agent for Sleep Disorder
#501DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION
#502MULTIPARTICULATE CONTROLLED RELEASE SELECTIVE SEROTONIN REUPTAKE INHIBITOR FORMULATIONS
#503PHARMACEUTICAL COMPOSITION COMPRISING, IN COMBINATION, SAREDUTANT AND ESCITALOPRAM
#504PHARMACEUTICAL COMPOSITION COMPRISING, IN COMBINATION, SAREDUTANT AND PAROXETINE
#505Cyanooxime inhibitors of carbonyl reductase and methods of using said inhibitors in treatments involving anthracyclines
#506COMBINATION OF A LONG-ACTING HYPNOTIC AGENT AND A SHORT-ACTING HYPNOTIC AGENT AND THERAPEUTIC USE THEREOF
#507Methods and compositions using cholinesterase inhibitors
#508Novel formulations of alpha-2,4-disulfophenyl-N-tert-butylnitrone
#509PAN-ALPHA-2 RECEPTOR AGONIST AND RELAXANT COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS
#510Modified Release Formulations Of Selective Serotonin Re-Uptake Inhibitors
#511Treatment of diabetes with copper binding compounds
#512Method of modulating cellular activity and agents useful for same
#513Composition and method for inducing or restoring locomotor functions in an animal
#514ANTIALLERGIC AGENTS
#515METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DEPRESSION
#516Polyamine compounds
#517PHARMACEUTICAL COMPOSITION COMPRISING, IN COMBINATION, SAREDUTANT AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR OR A SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITOR
#518Method for treating a motor neuron disease
#519Pharmaceutical Compositions Comprising Droxidopa
#520Treating psychological conditions using muscarinic receptor Mantagonists
#521Tuberculosis treatment using pleuromutilin derivatives
#522Total enteral nutritious composition
#523Methods for altering insulin secretion
#524Propofol analogs, process for their preparation, and methods of use
#525Antiallergic agents
#526Antiallergic agents
#527Use of chk1 inhibitors to control cell proliferation
#528Association between a heterocyclic compound and an antioxidant agent
#529COMPOSITIONS CONTAINING SUBSTITUTED QUINOLINES AND SUBSTITUTED DIPHENYL SULFONES AND METHODS OF USE
#530Compositions and methods for reducing food cravings
#531S-adenosyl methionine decarboxylase inhibition for the treatment of a herpes simplex virus infection
#532Resonance modulator for diagnosis and therapy
#533Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same
#534Hydrazide substrate shuts down protein biosynthesis capability in cells that host a metastatic or malignant disease mechanism
#535Hydrazone derivative
#536Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
#537Method and probe for identifying bacterial virulence modifying agents, agents thus identified, and their use
#538Antiallergic
#539Medicament for treatment of diabetes
#540Inhibitors against the activation of ap-1 and nfat
#541Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition
#542Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists
#543Compositions and methods containing substituted quinolines and substituted diphenylsulfones
#544Use of curcumanoids as histone acetyltransferases (HATs) inhibitors
#545Methods and compositions using cholinesterase inhibitors
#546Methods for reducing hospitalizations related to heart failure
#547Compositions and methods related to heart failure
#548Spin trapping pharmaceutical compositions and methods for use thereof
#549Combination of dopamine agonists and monoamine reuptake inhibitors
#550Topical composition comprising at least one aryl oxime and bisabolol
#551Methods for treating multiple sclerosis and pharmaceutical compositions therefor
#552Tuberculosis treatment
#553Agents which interact with a serotonin transporter for the treatment of cancer
#554Treatment of diabetes with copper binding compounds
#555Use of 20-HETE synthesizing enzyme inhibitors as therapy for cerebral vascular disease
#556Benzylcycloalkyl amines as modulators of chemokine receptor activity
#557Spin trapping pharmaceutical compositions and methods for use thereof
#558Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
#559As-needed administration of an androgenic agent to enhance female desire and responsiveness
#560Polyamine compounds for treating chemokine receptor mediated diseases
#561Methods for treating glaucoma
#562Methods of extending mammalian life span via iron chelating compounds that reduce free radical damage in mammals
#5631-naphthalenyl aminoethyl Schiff base and use as a death ligand-1 inhibitor
#564Method of treating cancer in a subject
#5658-(2-hydroxybenzylideneamino)naphthalene-1,3-disulfonic acid as an antioxidant compound
#566Systems and methods for treatment of hearing using dihexa
#567Compositions and methods for modulating the endothelial barrier
#568Methods, compositions and devices for treating cancer with illudofulvenes
#569Substituted naphthyridinyl hydrazines as anti-liver cancer agents